Thu, June 4, 2026
AUS Edition NZ Edition UK Edition
CA Edition USA Edition IND Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. VCEL
Healthcare
Facebook Twitter Linkedin

Vericel Corp Ord (NASDAQ:VCEL)

34.74 USD

+0.290 0.842%
Last Updated at: 2026-06-03T20:00:00Z

Vericel Corp Ord

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

64 Sidney Street, Cambridge, MA, United States, 02139

617 588 5555

https://vcel.com

Employees: 314

Key Executives

Sr. No. Name Title Year Born
1. Mr. Dominick C. Colangelo Esq. CEO, Pres & Director 1964
2. Mr. Joseph Anthony Mara Jr. CFO & Treasurer 1976
3. Mr. Michael Halpin Chief Operating Officer 1961
4. Mr. Sean C. Flynn Sr. VP, Gen. Counsel & Sec. 1974
5. Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. Chief Medical Officer 1962
6. Mr. Jonathan Siegal Principal Accounting Officer, VP & Corp. Controller NA
7. Mr. Eric Burns Exec. Director of Financial Planning and Analysis & Investor Relations NA
8. Mr. Patrick J. Fowler Sr. VP of Corp. Devel. & Strategy NA
9. Ms. Heidi Hassen VP of HR NA
10. Mr. Roland DeAngelis Sr. VP of Commercial Operations NA

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
NVO

Novo Nordisk A/S

 -0.920 2.144% 42.715 41.580 31.153 2.134 32.989 2.113 4.700
NONOF

Novo Nordisk A/S

 -0.750 1.734% 42.5 41.060 31.250 2.078 33.111 2.113 4.700
VRTX

Vertex Pharmaceuticals Inc

 +3.250 0.765% 420.63 29.670 24.331 10.385 5.832 9.334 20.004
REGN

Regeneron Pharmaceuticals Inc

 +16.030 2.659% 600.79 29.070 20.121 7.570 3.823 6.950 19.423

Income Statement

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Income Before Tax -15.988M -7.582M 3.044M -9.665M -8.137M
Minority Interest - - - - -
Net Income -16.709M -7.471M 2.864M -7.909M -8.137M
Selling General Administrative 106.903M 97.592M 68.836M 61.139M 49.007M
Gross Profit 109.788M 106.025M 84.228M 80.279M 58.697M
Reconciled Depreciation 3.981M 2.965M 2.383M 1.744M 1.426M
Ebit -17.058M -7.854M 0.667M -11.251M -4.469M
Ebitda -15.622M -7.578M 3.05M -9.657M -3.043M
Depreciation And Amortization 1.436M 0.276M 2.383M 1.594M 1.426M
Operating Income -17.058M -7.854M 0.667M -11.251M -3.909M
Other Operating Expenses 181.423M 164.038M 121.807M 129.101M 94.766M
Interest Expense 0.366M 0.004M 0.006M 0.008M 1.732M
Tax Provision 0.721M -0.111M 0.18M - -
Interest Income 1.341M 0.224M 0.691M 1.614M 0.897M
Net Interest Income 0.975M 0.22M 0.685M 1.606M -0.835M
Income Tax Expense 0.721M -0.111M 0.18M -1.756M 3.362M
Total Revenue 164.365M 156.184M 124.179M 117.85M 90.857M
Total Operating Expenses 126.846M 113.879M 81.856M 91.53M 62.606M
Cost Of Revenue 54.577M 50.159M 39.951M 37.571M 32.16M
Total Other Income Expense Net 1.07M 0.272M 2.377M 1.586M -3.393M
Net Income From Continuing Ops -16.709M -7.471M 2.864M -9.665M -8.137M
Net Income Applicable To Common Shares -16.709M -7.471M 2.864M -9.665M -8.137M

Balance Sheet

(Currency in USD)
Breakdown 31-12-2023 31-12-2022 31-12-2021 31-12-2020 31-12-2019
Total Assets 353.657M 273.003M 243.705M 205.608M 153.238M
Intangible Assets 6.875M 7.5M - - -
Other Current Assets 6.853M 4.803M 4.246M 3.893M 2.953M
Total Liab 127.705M 80.731M 73.243M 71.348M 42.147M
Total Stockholder Equity 225.952M 192.272M 170.462M 134.26M 111.091M
Other Current Liab 17.215M 16.231M 0.041M 0.041M 0.041M
Common Stock 629.229M 593.245M 553.902M 510.061M 489.749M
Capital Stock 629.229M 593.245M 553.902M 510.061M 489.749M
Retained Earnings -403.177M -399.995M -383.286M -375.815M -378.679M
Good Will - - - - -
Other Assets 0M 1.303M 0.528M 57.919M 0.089M
Cash 86.866M 51.067M 68.33M 33.62M 26.889M
Cash And Equivalents - - - - -
Total Current Liabilities 45.749M 37.463M 26.052M 22.483M 19.795M
Current Deferred Revenue - - 14.045M 11.293M 7.948M
Net Debt 1.277M -3.497M -18.233M 19.563M 0.814M
Short Term Debt 6.187M 4.302M 2.95M 4.394M 5.461M
Short Long Term Debt - - - - -
Short Long Term Debt Total 88.143M 47.57M 50.097M 53.183M 27.703M
Other Stockholder Equity - 592.267M 177.933M 127.614M 0.021M
Property Plant Equipment - 57.372M 59.028M 57.738M 32.247M
Total Current Assets 205.631M 186.866M 158.462M 123.56M 111.655M
Long Term Investments 25.283M 19.962M 25.687M 24.099M 9.247M
Short Term Investments 40.469M 68.471M 35.068M 42.187M 42.829M
Net Receivables 58.356M 46.539M 37.437M 34.504M 32.168M
Long Term Debt - - - - -
Inventory 13.087M 15.986M 13.381M 9.356M 6.816M
Accounts Payable 22.347M 16.93M 9.016M 6.755M 6.345M
Accumulated Other Comprehensive Income -0.1M -0.978M -0.154M 0.014M 0.021M
Non Currrent Assets Other 0.771M 1.303M 0.528M 0.211M 0.089M
Non Current Assets Total 148.026M 86.137M 85.243M 82.048M 41.583M
Capital Lease Obligations 88.043M 47.611M 50.182M 53.3M 27.854M
Long Term Debt Total - - - - 0.11M

Cash Flow

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Investments -36.206M 4.414M -14.534M 13.231M -64.349M
Total Cashflows From Investing Activities -36.206M -3.501M -17.16M 10.615M -67.027M
Total Cash From Financing Activities 1.045M 9.171M 6.441M 5.26M 58.863M
Net Income -16.709M -7.471M 2.864M -9.665M -8.137M
Change In Cash -17.474M 34.71M 6.853M 8.692M -8.576M
Begin Period Cash Flow 68.541M 33.831M 26.978M 18.286M 26.862M
End Period Cash Flow 51.067M 68.541M 33.831M 26.978M 18.286M
Total Cash From Operating Activities 17.687M 29.04M 17.572M -7.183M -0.412M
Depreciation 3.981M 2.965M 2.383M 1.744M 1.426M
Other Cashflows From Investing Activities - - - 13.231M -64.349M
Dividends Paid - - - - -
Change To Inventory -2.605M -4.025M -2.54M -3.258M 0.235M
Sale Purchase Of Stock 3.652M 11.184M 6.632M 5.286M 77.105M
Other Cashflows From Financing Activities -2.607M -2.013M 6.441M 5.26M 2.006M
Capital Expenditures 7.596M 7.915M 2.626M 2.616M 2.678M
Change In Working Capital -11.209M -6.154M -6.374M -14.66M -4.032M
Other Non Cash Items 3.72M 4.429M 4.445M 2.787M 3.108M
Free Cash Flow 10.091M 21.125M 14.946M -9.799M -3.09M

Funds

Sr. No. Name Purchased On Shares
1. Brown Capital Mgmt Small Co Inv 2 years ago 3869381
2. iShares Core S&P Small-Cap ETF 2 years ago 3223240
3. Conestoga Small Cap Investors 2 years ago 1612200
4. Vanguard Total Stock Mkt Idx Inv 2 years ago 1503267
5. SPDR® S&P Biotech ETF 2 years ago 1443696
6. iShares Russell 2000 ETF 2 years ago 1169081
7. Vanguard Institutional Extnd Mkt Idx Tr 2 years ago 710748
8. Conestoga Small Cap Growth 2 years ago 660479
9. Delaware Ivy Small Cap Growth C 2 years ago 655928
10. Loomis Sayles Small Cap Growth Instl 2 years ago 644126
11. Fidelity Small Cap Growth 2 years ago 632068
12. BNP Paribas Health Cr Innovtr Cl Cap 2 years ago 626765
13. Fidelity Small Cap Index 2 years ago 482100
14. Congress Small Cap Growth Institutional 2 years ago 470000
15. iShares S&P Small-Cap 600 Growth ETF 2 years ago 466517
16. JPM Thematics Genetic Thrps C2 Acc USD 2 years ago 446757
17. SPDR® Portfolio S&P 600 Sm Cap ETF 2 years ago 422357
18. iShares Russell 2000 Growth ETF 2 years ago 413046
19. Vanguard Tax-Managed Small Cap Adm 2 years ago 366185
20. iShares Biotechnology ETF 2 years ago 355896

Institutions

Sr. No. Name Purchased On Shares
1. Brown Capital Management, LLC 2 years ago 4950943
2. Vanguard Group Inc 2 years ago 3413442
3. State Street Corporation 2 years ago 2664883
4. Conestoga Capital Advisors, LLC 2 years ago 2331310
5. RTW INVESTMENTS, LLC 2 years ago 1606397
6. Morgan Stanley - Brokerage Accounts 2 years ago 1297846
7. GW&K Investment Management, LLC 2 years ago 1225676
8. Macquarie Group Ltd 2 years ago 1146193
9. Loomis, Sayles & Company LP 2 years ago 1141526
10. New York State Common Retirement Fund 2 years ago 1061361
11. Geode Capital Management, LLC 2 years ago 1027379
12. Goldman Sachs Group Inc 2 years ago 944390
13. BNP Paribas Investment Partners SA 2 years ago 920898
14. William Blair Investment Management, LLC 2 years ago 841677
15. Congress Asset Management Company, LLP 2 years ago 836481
16. JPMorgan Chase & Co 2 years ago 691630
17. Geneva Capital Management 2 years ago 679165
18. Ameriprise Financial Inc 2 years ago 675222
19. Dimensional Fund Advisors, Inc. 2 years ago 641215
20. BlackRock Inc 2 years ago 7937063
Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Sponsored Articles

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App